Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer

The aim of this phase I/II study was to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities of chronic oral etoposide given on days 1–10 followed by rescue with subcutaneous (s.c.) granulocyte-macrophage colony-stimulating factor (GM-CSF) on days 12–19 as second-line chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Baur, M, Schernhammer, E, Gneist, M, Sevelda, P, Speiser, P, Hudec, M, Dittrich, Ch
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361931/
https://www.ncbi.nlm.nih.gov/pubmed/15756278
http://dx.doi.org/10.1038/sj.bjc.6602427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361931/
https://www.ncbi.nlm.nih.gov/pubmed/15756278
http://dx.doi.org/10.1038/sj.bjc.6602427

Ejemplares similares